Company / Gross Profit
AYTU BIOPHARMA, INC Gross Profit History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$45.8M
FY2025
5-year range
$29.2M / $66.6M
FY2021-FY2025
Trend
-6.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $67M to $46M over the past 2 years.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of +18.8%.
Declined from $67M to $46M over the past 2 years.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -4.3%
- 5-Year CAGR
- +18.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +18.8%, indicating consistent growth.
- In FY2025, gross profit decreased 6.6% year-over-year.
- Peak gross profit was recorded in FY2023.
- Lowest gross profit in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.8M | -6.6% |
| FY2024 | $49.1M | -26.4% |
| FY2023 | $66.6M | +27.4% |
| FY2022 | $52.3M | +79.1% |
| FY2021 | $29.2M | +50.9% |
| FY2020 | $19.4M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026